Hua Medicine 02552
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HKD 1.59
- Day Range
- HKD 1.55–1.62
- 52-Week Range
- HKD 1.29–2.96
- Bid/Ask
- HKD 1.59 / HKD 1.61
- Market Cap
- HKD 1.58 Bil
- Volume/Avg
- 590,000 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 18.56
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Hua Medicine is an investment holding company. It is engaged in development and commercialization of a global first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC. Some of its products are Dorzagliatin + Metformin, Dorzagliatin, Dorzagliatin + Pioglitazone and mGLUR5 NAM, among others.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 177
- Website
- https://www.huamedicine.com
Comparables
Valuation
|
Metric
|
02552
|
RGC
|
03692
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 30.76 |
Price/Book Value | — | 5.77 | 3.86 |
Price/Sales | 18.56 | — | 9.85 |
Price/Cash Flow | — | — | 34.89 |
Price/Earnings
02552
RGC
03692
Financial Strength
|
Metric
|
02552
|
RGC
|
03692
|
|---|---|---|---|
Quick Ratio | 3.53 | 19.15 | 4.10 |
Current Ratio | 3.80 | 19.15 | 4.21 |
Interest Coverage | −36.00 | — | 43.91 |
Quick Ratio
02552
RGC
03692
Profitability
|
Metric
|
02552
|
RGC
|
03692
|
|---|---|---|---|
Return on Assets (Normalized) | −14.39% | −33.37% | 10.81% |
Return on Equity (Normalized) | — | −35.23% | 14.31% |
Return on Invested Capital (Normalized) | −55.97% | −34.27% | 9.41% |
Return on Assets
02552
RGC
03692
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Kzhbcvybqc | Cstl | $76.2 Bil | |
MKKGY
| Merck KGaA ADR | Ybsglxjl | Qwmfbk | $70.9 Bil | |
HLN
| Haleon PLC ADR | Rnfnscrh | Grx | $37.8 Bil | |
VTRS
| Viatris Inc | Qtztkwt | Hpms | $14.0 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Vwqxzhb | Nxsb | $12.7 Bil | |
CTLT
| Catalent Inc | Ztnvmbs | Sgpsxb | $10.2 Bil | |
PRGO
| Perrigo Co PLC | Svyyhtvvx | Rnbd | $4.4 Bil | |
CURLF
| Curaleaf Holdings Inc | Kwjwpyrfy | Vvf | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Nxsscqbp | Nknrvd | $3.5 Bil | |
GTBIF
| Green Thumb Industries Inc | Mrqvsjxhjd | Cjkv | $3.1 Bil |